phase III trial
A phase III trial is the big, decisive exam a drug must pass before regulators will let it be sold. Earlier phases gathered hints; phase III is built to deliver a verdict solid enough to change medical practice and to support approval. It is large, rigorous, and expensive precisely because so much rides on getting the answer right.
These trials enroll hundreds to many thousands of patients, often across many hospitals and countries, so the result reflects a realistically diverse population. The new drug is compared against a placebo or, more often, the current best treatment, with patients randomized between groups and the trial usually blinded. Crucially, phase III tends to measure outcomes that matter directly to patients, such as fewer heart attacks, longer survival, or fewer relapses, rather than relying only on surrogate lab markers.
The large size does double duty. It provides the statistical power to detect a true treatment effect and to estimate its magnitude with reasonable precision, and it exposes enough people to reveal adverse effects too uncommon to have appeared earlier. Regulators typically expect convincing evidence, often from more than one well-conducted study, before granting approval.
Even a successful phase III trial is not the last word. It still studies eligible, consenting, closely monitored patients, who may differ from the frailer or more complicated people treated afterward, and very rare risks may need millions of real-world exposures to emerge, which is why monitoring continues after the drug reaches the market.
A phase III trial of a new anticoagulant randomizes 18,000 patients with atrial fibrillation to the drug or warfarin and tracks strokes and major bleeds for two years to prove it is at least as good and as safe.
Large, outcome-focused phase III data form the backbone of a marketing application.
Phase III is often called the pivotal or registration trial because its results form the core evidence a regulator weighs when deciding whether to approve a drug.